GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Profitability Rank

Laekna (HKSE:02105) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Profitability Rank?

Laekna has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Laekna's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Laekna's Piotroski F-Score is 5.


Competitive Comparison of Laekna's Profitability Rank

For the Biotechnology subindustry, Laekna's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Laekna's Profitability Rank falls into.



Laekna Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Laekna has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Laekna's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Laekna has an F-score of 5 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Laekna Profitability Rank Related Terms

Thank you for viewing the detailed overview of Laekna's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna (HKSE:02105) Business Description

Traded in Other Exchanges
N/A
Address
No. 987, Cailun Road, 5th Floor, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Liu Zeng 2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Liu Ying 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna (HKSE:02105) Headlines

No Headlines